Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 640 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now... October 29, 2021 Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué... July 13, 2022 Νέα για τον καρκίνο του προστάτη June 9, 2019 NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... April 13, 2022 Load more HOT NEWS Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... Reflections on Progress and Partnership at ASCO 2026 News digest – targeted radiation beam, precision medicine and our early...
